Recent macro briefings have been dominated by energy market dynamics rather than healthcare-specific developments. Oil prices extended gains for a fourth consecutive session on 15 July 2026, with Brent crude rising 0.83% above $85 per barrel and WTI climbing 0.89% above $80, driven by Middle East supply concerns following the collapse of US-Iran negotiations. The cumulative advance reached approximately 12% over the period, contributing to a broader risk-sensitive tone across European and US sessions [Brief - 2026-07-15].
Johnson & Johnson's trailing twelve-month revenue stood at $97.93 billion as of 28 June 2026, representing year-over-year growth of 6.60%. Net income for the same period was $21.04 billion, yielding a net margin of 21.48%. Gross margin was recorded at 67.91% and operating margin at 27.37%. Earnings per share declined 0.87% year-over-year. The company held $20.42 billion in cash against total debt of $49.04 billion. The price-to-earnings ratio was 30.11 at the reporting date [SEC 10-Q - JNJ - 2026-06-28].
Insider activity over the past 30 days recorded three transactions with a net selling direction, totalling a net disposal value of approximately $5.79 million [SEC Form 4 - JNJ - 2026-07]. No 13F institutional holding changes were available in the provided data for this reporting period.
The prevailing macro environment features a 10-year US Treasury yield of 4.67% and a 2-year yield of 4.31%, producing a normal yield curve spread of 36 basis points [FRED DGS10] [FRED DGS2]. This report was generated in response to a new SEC filing submitted in connection with Johnson & Johnson's most recent reporting period.